Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not: A Langendorff Study

Charles Mackin, Elizabeth S. DeWitt, Katherine J. Black, Xiaoqi Tang, Brian D. Polizzotti, Sarah J. van den Bosch, Mark E. Alexander, John N. Kheir

Research output: Contribution to journalArticle

Abstract

Introduction: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Methods: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m2/d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dTmax), diastolic performance (dP/dTmin), and heart rate were compared between groups over time by linear mixed modeling. Results: Compared with placebo, sotalol decreased contractility by an average of 24% (P <.001) over the infusion period, as did amiodarone (low dose by 13%, P =.029; high dose by 14%, P =.013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22%, P =.016) and esmolol 200 μg/kg/min (by 23%, P =.012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, β = −89 [−144, −33] μL/min2 decrease, P =.002) and also worsened diastolic function, decreasing dP/dTmin by ∼18% and 22% (P =.032 and P =.011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. Conclusions: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.

Original languageEnglish (US)
Pages (from-to)288-297
Number of pages10
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume24
Issue number3
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Sotalol
Procainamide
Amiodarone
Cardiac Output
Placebos
Critical Illness
Sprague Dawley Rats
Heart Rate

Keywords

  • antiarrhythmic
  • contractility
  • intensive care

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not : A Langendorff Study. / Mackin, Charles; DeWitt, Elizabeth S.; Black, Katherine J.; Tang, Xiaoqi; Polizzotti, Brian D.; van den Bosch, Sarah J.; Alexander, Mark E.; Kheir, John N.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 24, No. 3, 01.05.2019, p. 288-297.

Research output: Contribution to journalArticle

Mackin, Charles ; DeWitt, Elizabeth S. ; Black, Katherine J. ; Tang, Xiaoqi ; Polizzotti, Brian D. ; van den Bosch, Sarah J. ; Alexander, Mark E. ; Kheir, John N. / Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not : A Langendorff Study. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2019 ; Vol. 24, No. 3. pp. 288-297.
@article{a3f134ef358944149d3f0afb79003ada,
title = "Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not: A Langendorff Study",
abstract = "Introduction: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Methods: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m2/d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dTmax), diastolic performance (dP/dTmin), and heart rate were compared between groups over time by linear mixed modeling. Results: Compared with placebo, sotalol decreased contractility by an average of 24{\%} (P <.001) over the infusion period, as did amiodarone (low dose by 13{\%}, P =.029; high dose by 14{\%}, P =.013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22{\%}, P =.016) and esmolol 200 μg/kg/min (by 23{\%}, P =.012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, β = −89 [−144, −33] μL/min2 decrease, P =.002) and also worsened diastolic function, decreasing dP/dTmin by ∼18{\%} and 22{\%} (P =.032 and P =.011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. Conclusions: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.",
keywords = "antiarrhythmic, contractility, intensive care",
author = "Charles Mackin and DeWitt, {Elizabeth S.} and Black, {Katherine J.} and Xiaoqi Tang and Polizzotti, {Brian D.} and {van den Bosch}, {Sarah J.} and Alexander, {Mark E.} and Kheir, {John N.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1177/1074248418810811",
language = "English (US)",
volume = "24",
pages = "288--297",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Intravenous Amiodarone and Sotalol Impair Contractility and Cardiac Output, but Procainamide Does Not

T2 - A Langendorff Study

AU - Mackin, Charles

AU - DeWitt, Elizabeth S.

AU - Black, Katherine J.

AU - Tang, Xiaoqi

AU - Polizzotti, Brian D.

AU - van den Bosch, Sarah J.

AU - Alexander, Mark E.

AU - Kheir, John N.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Introduction: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Methods: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m2/d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dTmax), diastolic performance (dP/dTmin), and heart rate were compared between groups over time by linear mixed modeling. Results: Compared with placebo, sotalol decreased contractility by an average of 24% (P <.001) over the infusion period, as did amiodarone (low dose by 13%, P =.029; high dose by 14%, P =.013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22%, P =.016) and esmolol 200 μg/kg/min (by 23%, P =.012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, β = −89 [−144, −33] μL/min2 decrease, P =.002) and also worsened diastolic function, decreasing dP/dTmin by ∼18% and 22% (P =.032 and P =.011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. Conclusions: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.

AB - Introduction: Direct comparison of the effects of antiarrhythmic agents on myocardial performance may be useful in choosing between medications in critically ill patients. Studies directly comparing multiple antiarrhythmic medications are lacking. The use of an experimental heart preparation permits examination of myocardial performance under constant loading conditions. Methods: Hearts of Sprague Dawley rats (n = 35, 402-507 g) were explanted and cannulated in working heart model with fixed preload and afterload. Each heart was then exposed to a 3-hour infusion of procainamide (20 µg/kg/min), esmolol (100 or 200 µg/kg/min), amiodarone (10 or 20 mg/kg/d), sotalol (80 mg/m2/d), or placebo infusions (n = 5 per dose). Cardiac output, contractility (dP/dTmax), diastolic performance (dP/dTmin), and heart rate were compared between groups over time by linear mixed modeling. Results: Compared with placebo, sotalol decreased contractility by an average of 24% (P <.001) over the infusion period, as did amiodarone (low dose by 13%, P =.029; high dose by 14%, P =.013). Compared with placebo, mean cardiac output was significantly lower in animals treated with sotalol (by 22%, P =.016) and esmolol 200 μg/kg/min (by 23%, P =.012). Over time, amiodarone decreased cardiac output (20 mg/kg/d, β = −89 [−144, −33] μL/min2 decrease, P =.002) and also worsened diastolic function, decreasing dP/dTmin by ∼18% and 22% (P =.032 and P =.011, low and high doses, respectively). Procainamide did not have a significant effect on any measures of systolic or diastolic performance. Conclusions: In isolated hearts, amiodarone and sotalol depressed myocardial contractility, cardiac output, and diastolic function. However, procainamide did not negatively affect myocardial performance and represents a favorable agent in settings of therapeutic equivalence.

KW - antiarrhythmic

KW - contractility

KW - intensive care

UR - http://www.scopus.com/inward/record.url?scp=85059018817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059018817&partnerID=8YFLogxK

U2 - 10.1177/1074248418810811

DO - 10.1177/1074248418810811

M3 - Article

C2 - 30497293

AN - SCOPUS:85059018817

VL - 24

SP - 288

EP - 297

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 3

ER -